Tuesday, July 23, 2019 4:48:49 PM
Alfasigma agrees with Innovation Pharmaceuticals for develop and market Brilacidin in the treatment of Ulcerative Proctitis and Ulcerative Proctosigmoiditis • Innovation Pharmaceuticals & Alfasigma announced an agreement for Brilacidin, in the treatment of Ulcerative Proctitis and Ulcerative Proctosigmoiditis • For Alfasigma it is the second agreement in a few weeks that strengthens pipeline and portfolio in the Gastrointestinal field • The agreement starts from a base of 24 million dollars Bologna, July 23, 2019 - Alfasigma Spa and Innovation Pharmaceuticals (OTCQB:IPIX), a biopharmaceutical company based in the United States, have entered into a licensing agreement for which Alfasigma will develop and market worldwide Brilacidin for use local, for the treatment of Ulcerative Proctitis and Ulcerative Proctosigmoiditis (PU / PSU). There Proctitis is an inflammatory disease of the rectum, which when extended also to sigma is called Proctosigmoidite. PU and PSU are therefore attributable to chronic intestinal inflammatory diseases (MICI, also known as IBD - Inflammatory Bowel Disease: together they represent one chronic and autoimmune condition difficult to treat affecting about 10 million people
all over the world, including 200,000 people in Italy. Brilacidin will be developed as a new non-corticosteroid, non-biological treatment, administered by different formulations, Alfasigma will initially develop topical formulations such as enema, foams and / or gel for PU / PSU.
A few weeks after the announcement for the commercial re-introduction of Zelnorm in the States - used for the treatment of irritable bowel syndrome constipation - this is a further step in strengthening the pipeline in the Gastro-intestinal area.
"Alfasigma is developing, at a global level, a specific focus in the Gastrointestinal field", stated Pier Vincenzo Colli, CEO of Alfasigma. "We are excited to add to the our portfolio, this partnership with Innovation Pharmaceuticals. The results of the study clinical on Phase 2 Brilacidin in PU / PSU seem promising and enhance properties unique of the drug. To advance Brilacidin, we plan to allocate an important one investment, both in terms of internal resources and expertise for formulations and protection of intellectual property. " "We are proud to be able to work to offer patients a new and effective option safe treatment in the management of PU / PSU ", continues Colli" We will also closely follow i next developments of Innovation Pharmaceuticals in the development of oral Brilacidin, why we are also interested in new treatments for mici. This agreement, along with that a few weeks ago on Zelnorm, represents a further enhancement of ours global pipeline ". The agreement also includes a right of first refusal for Brilacidin in the treatment of forms more extensive inflammatory bowel disease (IBD), such as ulcerative colitis and the Crohn's disease and a first negotiation right for Brilacidin in other gastrointestinal indications. In addition to an initial outlay, the agreement provides for a series of additional payments based on certain milestones, for a total of over $ 24 million and royalties of 6% on net sales in the marketing of Brilacidin for PU / PSU.
Information on Alfasigma. Alfasigma is one of the leading Italian pharmaceutical companies: present in over 90 countries, has a workforce of around 3,000 people, Research and Development laboratories, and 5 factories of production. In Italy Alfasigma is a leader in the market for prescription products where, in addition to the strong focus on Gastro-Intestinal, it is present in many primary care therapeutic areas. Produces and it also markets self-medication products, nutraceuticals and food supplements. For more information, visit www.alfasigma.com or send an e-mail to info@alfasigma.com.
Information on Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical biopharmaceutical company that
develops a portfolio of world-class innovative therapies that address multiple users
areas of unmet medical needs, including inflammatory diseases, cancer, infectious diseases
and dermatological diseases. More information is available on the company website
www.IPharmInc.com. Alfasigma Corporate Communications & Media Relations:
Biagio Oppi biagio.oppi@alfasigma.com +39 3386352349
Innovation Pharmaceuticals Investor & Media Relations:
Leo Ehrlich info@ipharminc.com
[url]https://www.alfasigma.com/CMSContent/Alfasigma/News/012%20ITA%20Brilacidin%20in%20Ulcerative%20Proctitis%20Ulcerative.pdf
[/url][tag]insert-text-here[/tag]
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM